Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit, Cerep Partner in Drug Discovery Venture

Premium

PARIS--ExonHit Therapeutics has entered into a two-year collaborative agreement with the drug-discovery company Cerep here. The partners will develop new methods for toxicity assessments, target validation, and drug discovery. Central to the agreement is ExonHit's proprietary Differential Analysis of Transcripts Alternatively Spliced (DATAS) technology. Under terms of the agreement, Cerep will make an equity investment of $500,000 in ExonHit and will fund research expenses up to $2.3 million based on the achievement of specific research and development milestones.

ExonHit is a qualitative gene profiling company started up here a year ago by three former Rhone-Poulenc Rorer R&D managers. The company received venture funding from CDC Innovation, Oxford BioSciences Partners, and Sofinnova Partners.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.